Who is a cardio-oncologist? Looking after the hearts of cancer patients before, during and long after cancer treatment.

Congratulations to Women As One board member Professor @lieslzuhlke on being named a 2026 L'Oréal-UNESCO For Women in Science Laureate! Recognized for improving care for children with rheumatic heart disease & advancing health equity. A well-deserved honor. #ForWomenInScience

Cardiovascular considerations AFTER cancer therapy🫀 The final paper in a 3 part #JACCCardioOnc Expert Panel series exploring cardiovascular care before, during, & after cancer therapy Cancer survivors remain at risk for future cardiovascular events throughout their lifespan. Key contributors include: 🫀Pre-existing CV risk factors: Lifestyle, genetics, family history, race/ethnicity 🫀Cancer treatment-related factors: 📍Cardiotoxic therapies 📍Pharmacokinetic factors 📍Epigenetic changes 🫀Emerging CV risk factors 📍Insulin resistance 📍Dyslipidemia 📍Hypertension 📍Reduced exercise capacity 🫀Long-term survivorship requires a multidisciplinary approach involving oncologists, cardiologists, cancer rehabilitation, primary care physicians, & geriatrics. Read more in @JACCJournals : jacc.org/doi/10.1016/j.jacca… #CardioOncology

Today, on #WorldBrainTumorDay, we honor the patients, families, and care teams facing one of oncology's most complex challenges – and we reflect on the critical role cardio-oncology plays in their journey. #CardioOncology #NeuroOncology #BrainTumor

Survivorship doesn't end at remission. The cardiovascular effects of #cancercare can follow patients for years. On #NationalCancerSurvivorsDay, we remain committed to protecting survivors' hearts before, during, and after treatment. #NCSD2026 #CancerSurvivor #CardioOncology

Can #AI predict cardiotoxicity before symptoms appear? Join @mayocvonc and the rest of the panel at #GCOS26 to explore how #artficialintelligence is reshaping #cardiooncology care. 🎟️ Save your spot: tinyurl.com/2dx225jt #CardioOnc #AIinHealthcare #ClinicalAI

Join us in Vienna and step into the future of cardio-oncology with the new EHJ-CardioOncology! 💣 Discover groundbreaking insights, connect with leading experts, and be part of the next chapter in cardiovascular care.

🧬Dyslipidaemia in cancer patients is an emerging challenge🚨 ASCVD risk is often underestimated, cancer therapies may severely alter lipid profiles and evidence for lipid-lowering strategies remains limited💊 Read more in #EHJ @ehj_ed 🔗doi.org/10.1093/eurheartj/eh… @TeresaLpezFdez1

Cardiovascular considerations BEFORE cancer therapy🫀 The first of a 3 part #JACCCardioOnc Expert Panel series exploring CV care before, during, & after cancer therapy. 🫀Goals of CV evaluation Prior to cancer therapy: 📍Identify and treat subclinical CVD and cardiovascular risk factors
📍Optimize management of pre-existing CVD and cardiovascular risk factors
📍Perform targeted risk assessment to help inform cancer treatment decisions
📍Establish baseline cardiovascular function
📍Optimize primary prevention therapies
📍Plan cardiovascular surveillance during treatment 🫀Current tools include clinical assessment, biomarkers, 12-lead ECG, #EchoFirst, & risk scores 🫀Important evidence gaps includes cardiotoxicity mechanisms, impact of pre-treatment CV evaluations on clinical outcomes, validation&implementation of risk scores, & the role of AI. Read more in @jaccjournals:
jacc.org/doi/10.1016/j.jacca… #CardioOncology

#COOL group of the @ESCardioOnco is a vibrant, young community for #CardioOncology leaders of tomorrow⏭️ Join our sessions at #ESCCardioOnc2026🇦🇹

🎟️ Early bird tickets for #GCOS26 are open – but only until June 30! Lock in the best rate before it's gone. Don't miss the #CardioOncology event of the year. Register now: gcos.ic-os.org/registration/ #cardioonc #Cardiology #HealthcareConference #MedTwitter

Join next week's #JACCCaridoOnc Journal Club on risk of #CVD in cancer survivors after systemic treatment! 🔬 Don’t miss this expert discussion with Drs. Nicholas Wilcox, Sivatharshini Ramalingam, and Frits Mulder! RSVP now: acc-org.zoom.us/meeting/regi… @drtarsh #CardioOnc

Your next step in #CardioOncology starts in Vienna, 19–20 June 🪜⬆️   Unmissable onsite opportunities. Real impact on patient care.   Join us at #ESCardioOnco26 — take the leap. 🌟bit.ly/4aWQpF0 #cardioonc #cardioonco #oncology #radiology @ESCardioOnco

Congratulations @MariaSolAndres1 @sohaibnazir and @ProfKausikRay on this landmark mansuscript on dyslipidaemia in #cancer patients #cardioonc #oncology #cardiooncology #cardiology #medtwitter #primarycare @ICOSociety @ESCardioOnco

To summarize a few key points (thanks @myelomatips @hhashmi87 @RahulBanerjeeMD @JanakiramMurali for weighing in): - Prophylactic IVIG for all with BCMA Bsabs - Prophylactic Toci (if you can get it approved) - GPRC5D has different AEs - Updated table 👇👇 #mmsm #HemeTwitter

🫘 Ajouter un nsMRA au RASi SGLT2i pourrait retarder l’insuffisance rénale de ~12 ans : 🔴 RASi SGLT2i seuls → DFGe atteint 10 mL/min vers ~16 ans 🟢 Trithérapie ( nsMRA) → DFGe atteint 10 mL/min vers ~28 ans Même DFGe de départ à 66.

🎧 How should we monitor the heart during HER2 breast cancer therapy? In this ESC CardioOncology #CardioTalk, Dr @Massimi78530343 & Dr @JLiu_MSKCardOnc discuss about HER2 cardiotoxicity, risk stratification, & monitoring to prevent #CTRCD 🎧: esc365.escardio.org/event/26…

Here is the list of drugs that we touched on during our #ToxCheck discussion with @JSabari & #AzamFarooqui on anti-EGFR in NSCLC! - Dose - Step down dosing - Common AEs #lcsm #OncTwitter #MedTwitter #LungCancer @OncUpdates

🚨Incident cancer in heart failure, myocardial infarction or both🫀: a report from a global federated research network 👇@ehj_ed @LucaMonzo @NicolasGirerd ow.ly/qNyn50YXiML